• Biohaven completed enrollment in RISE3, a pivotal Phase 2/3 trial of opakalim as add-on therapy for refractory focal epilepsy.
• Top-line results are expected in 2H 2026; interim data were previously presented, pointing to seizure reductions with generally favorable tolerability.
• The program targets a differentiated profile, aiming to control seizures without the sedation and other nervous-system side effects that often limit existing medicines.
• High completion and rollover into the open-label extension support patient acceptance, a key factor for positioning in a crowded epilepsy market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606300730PR_NEWS_USPR_____NE94948) on June 30, 2026, and is solely responsible for the information contained therein.